Active, not recruitingPhase 2NCT06018428

A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)

Studying Alopecia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Q32 Bio Inc.
Intervention
bempikibart (ADX-914)(drug)
Enrollment
75 enrolled
Eligibility
18-75 years · All sexes
Timeline
20232026

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06018428 on ClinicalTrials.gov

Other trials for Alopecia

Additional recruiting or active studies for the same condition.

See all trials for Alopecia

← Back to all trials